Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study

Background: The systemic treatment of advanced cutaneous squamous cell carcinoma (cSCC) has seen significant developments in recent years. The anti-PD1 inhibitor cemiplimab has demonstrated efficacy in clinical trials, but real-world data are still limited. Here, we aimed to evaluate the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuzmanovszki, Daniella, Kiss, Norbert, Tóth, Béla, Tóth, Veronika, Szakonyi, József, Lőrincz, Kende, Hársing, Judit, Kuroli, Enikő, Imrédi, Eleonóra, Kerner, Tünde, Patyánik, Mihály, Wikonkál, Norbert M., Szabó, Ákos, Brodszky, Valentin, Rencz, Fanni, Holló, Péter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531652/
https://www.ncbi.nlm.nih.gov/pubmed/37762907
http://dx.doi.org/10.3390/jcm12185966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531652/
https://www.ncbi.nlm.nih.gov/pubmed/37762907
http://dx.doi.org/10.3390/jcm12185966

Ejemplares similares